Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | D. Morrow | S. Murphy | D. Berg | P. Jarolim | C. Ruff | M. Grosso | David D. Berg | H. Lanz | K. Oyama | M. Tang | P. Jarolím
[1] T. Omland,et al. Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19 , 2020, Circulation.
[2] G. Lip,et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. , 2020, The New England journal of medicine.
[3] Jeroen J. Bax,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.
[4] J. Rivera‐Caravaca,et al. Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project , 2020, Thrombosis and Haemostasis.
[5] E. Antman,et al. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48 , 2019, Circulation.
[6] Tzeng-Ji Chen,et al. Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.
[7] G. Lip,et al. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores , 2017, Thrombosis and Haemostasis.
[8] B. Gersh,et al. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time , 2017, Journal of the American Heart Association.
[9] V. Cavalli,et al. GDF15 is elevated in mice following retinal ganglion cell death and in glaucoma patients. , 2017, JCI insight.
[10] E. Antman,et al. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. , 2016, JAMA cardiology.
[11] S. Yusuf,et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study , 2016, The Lancet.
[12] Claes Held,et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation , 2016, European heart journal.
[13] C. Granger,et al. Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial , 2014 .
[14] S. Yusuf,et al. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy , 2014, Heart.
[15] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[16] C. Granger,et al. Biomarkers in atrial fibrillation: a clinical review. , 2013, European heart journal.
[17] G. Lip,et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report , 2012, Chest.
[18] J. Cohn,et al. Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure: Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial , 2010, Circulation.
[19] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[20] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[21] M. Allessie,et al. Electrical, contractile and structural remodeling during atrial fibrillation. , 2002, Cardiovascular research.